tbuckley/cabot-search huggingface dataset:
THU0049 Is Patient Global Assessment in Boolean-Based Remission in Rheumatoid Arthritis Really Required Instead of Physician Global Assessment? A Comparative Study with Ultrasound
Authors: G. Ozen, A.U. Unal, A. Topcu, P. Atagunduz, H. Direskeneli, N. Inanc
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Patient global assessment (PtGA) is included in all the current remission definitions for RA despite the fact that PtGA is not exclusively related to disease activity. <h3>Objectives</h3> In this study in order to objectively identify whether patient9s assessment is better than physician9s (Ph) or not, we compared disease activities assessed with ultrasound (US) of Boolean remission patients with PtGA and with PhGA. <h3>Methods</h3> RA patients in clinical remission (DAS28 ESR&lt;2.6) for at least 3 months were included. Boolean based remission definition and modified version by substitution of PtGA with PhGA were determined. A standard gray scale (GS) and power Doppler (PD) US examination of 28 joints (included in DAS28) for the presence of synovitis was performed by an experienced sonographer (NI) blinded to clinical data. US synovitis GS and PD signals were semiquantitatively graded from 0 to 3 and were recorded as sum scores of PD and GS, respectively. <h3>Results</h3> A total of 88 out of 389 RA patients (22.6%) in DAS28 remission were enrolled (F/M=55/33, mean age 53.4±12.0, disease duration 10.5±6.3 years, bDMARDs 44.3%, RF/Anti-CCP positivity 72%). Of 88 patients, 33 (37.5%) fulfilled the Boolean remission criteria. When PtGA was substituted with PhGA, Boolean remission rate increased to 61.4% (n=54) (<i>P</i>&lt;0.001). Regarding US disease activity no PD, no GS and no PD+GS signals were observed in 13 (39.4%) vs 16 (29.6%), 10 (30.3%) vs 11 (20.4%) and 9 (27.3%) vs 10 (18.5%) patients in Boolean remission with PtGA and PhGA, respectively (Table 1). When PD and GS signals &gt; grade 1 were taken into account, % of patients without PD, GS or both signals were also similar Table 1). US disease activity parameters of Boolean PtGA and Boolean PhGA remission and their counterpart nonremission patients were compared as well, Boolean remission either with PtGA or PhGA had significantly lower PD scores compared to Boolean nonremission groups with PtGA or PhGA (1 [0–4] vs 3 [1–7], <i>P</i>=0.016 and 1.5 [0–4] vs 4 [0.75–7], <i>P</i>=0.027, respectively). <h3>Conclusions</h3> RA patients in Boolean remission with PhGA do not have higher disease activity that is verified by US, compared to patients in Boolean remission with PtGA. Furthermore Boolean remission with PhGA differentiates patients with US evinced inflammation, especially PD scores, as good as PtGA. These data suggest that PtGA might be substituted with PhGA in Boolean criteria with higher remission achievement rates. Prospective follow up and recruitment of more patients will clarify the consistency of these results over time and impact of this substitution on functionality. <h3>Disclosure of Interest</h3> None declared
CCR1 Blockade by An Orally-Available CCR1 Antagonist Reduces Tumor Burden and Osteolysis In Vivo In a Mouse Model of Myeloma Bone Disease
Authors: Babatunde Oyajobi, Daniel Dairaghi, Anjana Gupta, Brandon McCluskey, Yu Wang, Lisa C. Seitz, Jay P. Powers, Shichang Miao, Penglie Zhang, Thomas J. Schall, Juan C. Jaen
Journal: Blood (2010)
Comprehensive Analysis of Telomere Biology in Patients with Aplastic Anemia and Hypoplastic Myelodysplastic Syndrome: Further Evidence for a Common Mechanism
Authors: Anne-Sophie Bouillon, Monica S. Ferreira, Benjamin Werner, Sebastian Hummel, Jens P. Panse, Petra Reinecke, Jennifer Schemenau, Rainer Haas, Arne Traulsen, Tim H. Bruemmendorf, Ulrich Germing, Fabian Beier
Journal: Blood (2015)
SAT0479 Associations between Endogenous Sex Hormones and MRI Structural Changes in Patients with Symptomatic Knee Osteoarthritis
Authors: X. Jin, B.H. Wang, X. Wang, B.E. Antony, Z. Zhu, W. Han, F. Cicuttini, A. Wluka, T. Winzenberg, L. Blizzard, G. Jones, C. Ding
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Increased prevalence of knee osteoarthritis (OA) among postmenopausal women suggests involvement of endogenous hormones in pathogenesis. However, the effects of endogenous sex hormones on knee OA structures remain uncertain. <h3>Objectives</h3> To describe the longitudinal associations between serum levels of estrogen, progesterone and testosterone and knee structural changes using magnetic resonance imaging (MRI) in both males and females with symptomatic knee OA. <h3>Methods</h3> We examined 200 participants (mean age 63.0 ± 7.3 years) from a clinical trial of vitamin D supplement for symptomatic knee OA. Serum levels of estradiol, progesterone, testosterone and sex hormone binding globulin (SHBG) were analyzed at baseline and 24 months later. Magnetic resonance imaging (MRI) scans of the knees were obtained at both baseline and follow-up for the measurement of cartilage volume, cartilage defects, bone marrow lesions (BMLs) and effusion-synovitis volume. Knee pain was assessed using a 100mm visual analogue scale (VAS). Longitudinal data were analyzed using linear mixed-effects model. <h3>Results</h3> 107 males and 93 females were included in this study. For females, after adjustment for age, body mass index, and treatment allocation, progesterone was associated with cartilage volume (β =0.12 per quartile, p=0.01). Estradiol levels were associated with lower grades of BMLs (β = -0.45 per quartile, p=0.03), while estradiol (β = -1.26 per quartile, p=0.05), progesterone (β = -1.60 per quartile, p&lt;0.01) and testosterone (β = -1.49 per quartile, p=0.02) were inversely associated with effusion-synovitis volume for females. No consistent associations were observed for males. <h3>Conclusions</h3> Endogenous estradiol, progesterone and testosterone may be protective for joint structural changes in women but not men. This may contribute to observed sex differences in knee OA. <h3>Acknowledgement</h3> Jodi Barling, Kay Nguo, Judy Hankin and Alice Noone have been involved in the coordination of this study. Rob Warren measured knee cartilage volume. <h3>Disclosure of Interest</h3> None declared
Filterable Virus Diseases in Man.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Late Relapses of Childhood T-ALL Are Frequently Second T-ALL.
Authors: Tomasz Szczepanski, Vincent H.J. van der Velden, Pieter Van Vlierberghe, Bernd Gruhn, Renate Panzer-Grumayer, Monica Spinelli, Helene Cave, Udo zur Stadt, Dario Campana, Andre Schrauder, Elisabeth van Wering, Jules P.P. Meijerink, Jacques J.M. van Dongen
Journal: Blood (2007)
Therapy of B Cell Malignancies with CD19-Specific Chimeric Antigen Receptor-Modified T Cells of Defined Subset Composition
Authors: Cameron J Turtle, Daniel Sommermeyer, Carolina Berger, Michael Hudecek, David M Shank, Natalia N Steevens, Tanya M Budiarto, Mandana Karimi, Colette N Chaney, Anna Marie DeVito, Shelly Heimfeld, Michael C Jensen, Stanley R Riddell, David G Maloney
Journal: Blood (2014)
FRI0411 A Cross Sectional Study of The Clinical and Ultrasound Entheseal Involvement in Patients with IBD
Authors: E. Bertolini, P. Macchioni, M. Beltrami, F. Bassi, B. Marani, C. Salvarani, M. Catanoso
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Previous studies have reported the high prevalence of occult SpA in IBD patients. <h3>Objectives</h3> To investigate the presence of clinical and ultrasound peripheral entheseal abnormalities in a consecutive series of IBD patients. <h3>Methods</h3> 61 IBD consecutive patients [26 Crohn9s disease (CD) and 35 ulcerative colitis (UC), M/F 32/29, mean age 35.7+12.4 years, mean disease duration 57+93 months] entered the study. Gastroenterological examination consisted of the determination of bowel involvement, extraintestinal manifestations, MAYO and CDAI score. A complete rheumatological examination which included 66 peripheral join count, MASES and Leeds entheseal evaluation, BASDAI, BASFI and evaluation of spine mobility was done at study entry. ESR and CRP were evaluated at study entry. US examination was done using an Esaote MyLabClass, 18–6MHz linear multifrequence transducer both in gary scale and with PD. The following enthesis were separately studied clinical and US by two rheumatologist unaware of the other evaluation: lateral elbow epicondyle, distal quadricipital insertion at the patella, proximal and distal patellar tendon insertions, Achilles tendon an plantar fascia insertion at the calcaneous. Knee and ankle joints were evaluated for synovial hyertrophy, PD signal and fluid. Extensor and flexor tendons of the foot and ankle were evalutaed for the presence of tendon sheat fluid, synovial hypertrophy and PD signal. Quadriceps, patellar, Achille and plantar fascia entheses were scored according to the 0–36 Glasgow Ultrasound Enthesitis Scoring System (GUESS) and power Doppler (PD). Correlations of GUESS and PD with IBD features [duration, type (CD/UC) and activity (disease activity index for CD/Truelove score for UC)] were investigated. <h3>Results</h3> 29/61 (47.5%) patients had at leat one entheseal alteration at clinical examination and 56 (91.8%) presented almost one US entheseal abnormality with a mean 3.05±1.7 number of abnormal enthesis /patient. The mean MASEI was 11±9 and the mean GUESS 5.8±3.9 with 56/61 patients with value &gt;1. The US evidence of enthesitis was higer in CD with ileo-colon localization as compared to ileo or colon involvement (100% vs 89% and 50%, p=0.03). Patients with disease duration &gt;12 months have significantly grater number of cronical (2.48±1.5vs3.7±1.7, p=0.01) and acute enthseal alteration (3.0±1.3vs1.9±1.3,p=0.01) as compared with patients with disease duration &lt;12 months. <h3>Conclusions</h3> US entheseal abnormalities are present in a high percentage of IBD patients. US enthesopathy is associated with longer disease duration and topographical localization of gut disease. <h3>Disclosure of Interest</h3> None declared
Caveolin-1 in the regulation of cell metabolism: a cancer perspective
Authors: Zeribe Chike Nwosu, Matthias Philip Ebert, Steven Dooley, Christoph Meyer
Journal: Molecular Cancer (2016)

Caveolin-1 (CAV1) is an oncogenic membrane protein associated with endocytosis, extracellular matrix organisation, cholesterol distribution, cell migration and signaling. Recent studies reveal that CAV1 is involved in metabolic alterations - a critical strategy adopted by cancer cells to their survival advantage. Consequently, research findings suggest that CAV1, which is altered in several cancer types, influences tumour development or progression by controlling metabolism. Understanding the molecular interplay between CAV1 and metabolism could help uncover druggable metabolic targets or pathways of clinical relevance in cancer therapy. Here we review from a cancer perspective, the findings that CAV1 modulates cell metabolism with a focus on glycolysis, mitochondrial bioenergetics, glutaminolysis, fatty acid metabolism, and autophagy.
Whole genome sequence analysis of serum amino acid levels
Authors: Bing Yu, Paul S. de Vries, Ginger A. Metcalf, Zhe Wang, Elena V. Feofanova, Xiaoming Liu, Donna Marie Muzny, Lynne E. Wagenknecht, Richard A. Gibbs, Alanna C. Morrison, Eric Boerwinkle
Journal: Genome biology (2016)

Blood levels of amino acids are important biomarkers of disease and are influenced by synthesis, protein degradation, and gene-environment interactions. Whole genome sequence analysis of amino acid levels may establish a paradigm for analyzing quantitative risk factors.In a discovery cohort of 1872 African Americans and a replication cohort of 1552 European Americans we sequenced exons and whole genomes and measured serum levels of 70 amino acids. Rare and low-frequency variants (minor allele frequency ≤5%) were analyzed by three types of aggregating motifs defined by gene exons, regulatory regions, or genome-wide sliding windows. Common variants (minor allele frequency >5%) were analyzed individually. Over all four analysis strategies, 14 gene-amino acid associations were identified and replicated. The 14 loci accounted for an average of 1.8% of the variance in amino acid levels, which ranged from 0.4 to 9.7%. Among the identified locus-amino acid pairs, four are novel and six have been reported to underlie known Mendelian conditions. These results suggest that there may be substantial genetic effects on amino acid levels in the general population that may underlie inborn errors of metabolism. We also identify a predicted promoter variant in AGA (the gene that encodes aspartylglucosaminidase) that is significantly associated with asparagine levels, with an effect that is independent of any observed coding variants.These data provide insights into genetic influences on circulating amino acid levels by integrating -omic technologies in a multi-ethnic population. The results also help establish a paradigm for whole genome sequence analysis of quantitative traits.
Liberal Vs. Restrictive Transfusion Thresholds in Leukemia Patients: A Feasibility Pilot Study
Authors: Amy E. DeZern, Katherine Williams, Karen E. King, Wesley Hand, Mark J. Levis, B Doug Smith, Ivana Gojo, Keith W. Pratz, Lukasz P Gondek, Gabrielle T. Prince, Gabriel Ghiaur, Margaret M. Showel, Douglas Gladstone, Steve Frank, Paul M. Ness
Journal: Blood (2015)
Crosslinking of Fc Gamma-Rllb and Fc Epsilon-RI Binding Peptides Inhibits Osteoclast Formation in Multiple Myeloma through Inactivation of the ITAM Signaling Pathway
Authors: Haiming Chen, Mingjie Li, Eric Sanchez, Abigail Gillespie, Cathy Wang, Tiffany Lee, Suzie Vardanyan, Jason Nosrati, Jasmin Cao, Michael Zahab, Puja Mehta, George Tang, James Berenson
Journal: Blood (2015)
Impact of ABO Imcompatibility On Acute GvHD and Thrombotic Microangiopathy After Reduced-Intensity Cord Blood Transplantation.
Authors: Masanori Tsuji, Atsushi Wake, Naoyuki Uchida, Kazuya Ishiwata, Nobuaki Nakano, Shinsuke Takagi, Hisashi Yamamoto, Yuki Mori, Naofumi Matsuno, Kazuhiro Masuoka, Shigeyoshi Makino, Akiko Yoneyama, Shuichi Taniguchi
Journal: Blood (2009)
Reduced-Intensity Conditioning Regimen without Total Body Irradiation undergoing Umbilical Cord Blood Transplantation (non-TBI-RI-UCBT) Induces Successful Engraftment in Adult Patients with Advanced Hematological Malignancies.
Authors: Ko Miyamoto, Shigesaburo Miyakoshi, Aki Kyo, Koichiro Yuji, Eiji Kusumi, Fumiaki Sano, Shuichi Taniguchi, Haruhisa Nagosi
Journal: Blood (2004)
Rituximab, Fludarabine, and Cyclophosphamide (R-FC) Prolongs Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Compared with FC Alone: Final Results from the International Randomized Phase III REACH Trial
Authors: Tadeusz Robak, Sergey I Moiseev, Anna Dmoszynska, Philippe Solal-Céligny, Krzysztof Warzocha, Javier Loscertales, John Catalano, Boris V Afanasiev, Loree Larratt, Christian Geisler, Marco Montillo, Peter Ganly, Caroline Dartigeas, András Rosta, Ann Janssens, Myriam Mendila, Jörg Maurer, Michael K. Wenger
Journal: Blood (2008)
Randomized Phase II Study Evaluating the Efficacy and Safety of Deferasirox in Non-Transfusion-Dependent Thalassemia Patients with Iron Overload.
Authors: Ali Taher, John B. Porter, Antonis Kattamis, Vip Viprakasit, Tomasz Lawniczek, Raffaele Pereno, Oliver Schoenborn-Kellenberger, M. Domenica Cappellini
Journal: Blood (2009)
Chronic Hyperphosphatemia and Vascular Calcification Are Reduced by Stable Delivery of Soluble Klotho
Authors: Julia M. Hum, Linda M. O’Bryan, Arun K. Tatiparthi, Taryn A. Cass, Erica L. Clinkenbeard, Martin S. Cramer, Manoj Bhaskaran, Robert L. Johnson, Jonathan M. Wilson, Rosamund C. Smith, Kenneth E. White
Journal: Journal of the American Society of Nephrology (2016)

α Klotho ( α KL) regulates mineral metabolism, and diseases associated with α KL deficiency are characterized by hyperphosphatemia and vascular calcification (VC). α KL is expressed as a membrane-bound protein (mKL) and recognized as the coreceptor for fibroblast growth factor-23 (FGF23) and a circulating soluble form (cKL) created by endoproteolytic cleavage of mKL. The functions of cKL with regard to phosphate metabolism are unclear. We tested the ability of cKL to regulate pathways and phenotypes associated with hyperphosphatemia in a mouse model of CKD-mineral bone disorder and α KL -null mice. Stable delivery of adeno-associated virus (AAV) expressing cKL to diabetic endothelial nitric oxide synthase–deficient mice or α KL -null mice reduced serum phosphate levels. Acute injection of recombinant cKL downregulated the renal sodium-phosphate cotransporter Npt2a in α KL -null mice supporting direct actions of cKL in the absence of mKL. α KL -null mice with sustained AAV-cKL expression had a 74%–78% reduction in aorta mineral content and a 72%–77% reduction in mineral volume compared with control-treated counterparts ( P &lt;0.01). Treatment of UMR-106 osteoblastic cells with cKL + FGF23 increased the phosphorylation of extracellular signal–regulated kinase 1/2 and induced Fgf23 expression. CRISPR/Cas9-mediated deletion of fibroblast growth factor receptor 1 (FGFR1) or pretreatment with inhibitors of mitogen–activated kinase kinase 1 or FGFR ablated these responses. In summary, sustained cKL treatment reduced hyperphosphatemia in a mouse model of CKD-mineral bone disorder, and it reduced hyperphosphatemia and prevented VC in mice without endogenous α KL. Furthermore, cKL stimulated Fgf23 in an FGFR1-dependent manner in bone cells. Collectively, these findings indicate that cKL has mKL-independent activity and suggest the potential for enhancing cKL activity in diseases of hyperphosphatemia with associated VC.
Expression of Tcl-1 as a Potential Prognostic Factor for Treatment Outcome in B-Cell Chronic Lymphocytic Leukemia.
Authors: Rebekah E. Browning, David M. Lucas, Susan M. Geyer, Diane F. Jelinek, Renee C. Tschumper, Timothy G. Call, Tait D. Shanafelt, Clive S. Zent, Nancy D. Bone, Gordon W. Dewald, Thomas S. Lin, Nyla A. Heerema, Michael R. Grever, Neil E. Kay, John C. Byrd
Journal: Blood (2006)
WRN-targeted therapy using inhibitors NSC 19630 and NSC 617145 induce apoptosis in HTLV-1-transformed adult T-cell leukemia cells
Authors: R. Moles, X. T. Bai, H. Chaib-Mezrag, C. Nicot
Journal: Journal of Hematology & Oncology (2016)

Human T-cell leukemia virus type 1 (HTLV-1) infection is associated with adult T-cell leukemia/lymphoma (ATLL), a lymphoproliferative malignancy with a dismal prognosis and limited therapeutic options. Recent evidence shows that HTLV-1-transformed cells present defects in both DNA replication and DNA repair, suggesting that these cells might be particularly sensitive to treatment with a small helicase inhibitor. Because the "Werner syndrome ATP-dependent helicase" encoded by the WRN gene plays important roles in both cellular proliferation and DNA repair, we hypothesized that inhibition of WRN activity could be used as a new strategy to target ATLL cells. Our analysis demonstrates an apoptotic effect induced by the WRN helicase inhibitor in HTLV-1-transformed cells in vitro and ATL-derived cell lines. Inhibition of cellular proliferation and induction of apoptosis were demonstrated with cell cycle analysis, XTT proliferation assay, clonogenic assay, annexin V staining, and measurement of mitochondrial transmembrane potential. Targeted inhibition of the WRN helicase induced cell cycle arrest and apoptosis in HTLV-1-transformed leukemia cells. Treatment with NSC 19630 (WRN inhibitor) induces S-phase cell cycle arrest, disruption of the mitochondrial membrane potential, and decreased expression of anti-apoptotic factor Bcl-2. These events were associated with activation of caspase-3-dependent apoptosis in ATL cells. We identified some ATL cells, ATL-55T and LMY1, less sensitive to NSC 19630 but sensitive to another WRN inhibitor, NSC 617145. WRN is essential for survival of ATL cells. Our studies suggest that targeting the WRN helicase with small inhibitors is a novel promising strategy to target HTLV-1-transformed ATL cells.
SAT0161 The Retention Rate of Abatacept in Very Elderly Patients (75 Years and above) with Rheumatoid Arthritis, Single-Center, Retrospective, Observational Study
Authors: E. Kikuchi, K. Uekubo, N. Aoki, T. Yoshioka, T. Okai
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> There are few data about the safety of biologics for very elderly rheumatoid arthritis patients. <h3>Objectives</h3> To analyze the retention rate of abatacept in very elderly patients with rheumatoid arthritis (RA). <h3>Methods</h3> Data was collected retrospectively from medical records of RA patients in our center. Abatacept was administered in 58 patients. We divided them into two groups of the very elderly group (over 75 years old) and the remaining group (under 75 years old). We analyzed the retention rate of each group by Kaplan-Meier curves and log-rank test. <h3>Results</h3> In <i>the very elderly group</i> (29 cases: 81.6±3.3 years, women: 89.7%, ACPA-positive: 86.2%, MTX use: 48.3%, oral steroid use: 31.0%), the cumulative retention rates in 12 and 24 months were both 0.558. In <i>the remaining group</i> (29 cases: 63.4±10.7 years, women 89.7%, ACPA-positive: 86.2%, MTX use: 58.6%, oral steroid use: 37.9%), the cumulative retention rates in 12 and 24 months were 0.705 and 0.617 respectively. There was no significant difference in the retention rates in the two groups (log-rank test, p=0.913). Abatacept was administered as the first biologics in 58.6% of the very elderly group, 31.0% of the remaining group respectively. The main reasons for discontinuation of abatacept were hospitalization for infection (elderly: 3 cases, remaining: 2 cases) and hospitalization for gastrointestinal symptoms (elderly: 2, remaining: 0). <h3>Conclusions</h3> Our data suggested that abatacept can be used for a long period even for very elderly RA patients. <h3>References</h3> Lahaye C, et al. Rheumatology (Oxford). 2016 Jan 27. pii: kev437. [Epub ahead of print] <h3>Disclosure of Interest</h3> None declared
Impact of Chimerism and Other Transplant Variables on Allogeneic Transplant Outcome after Reduced Intensity Conditioning (RIC) Regimens.
Authors: Veronica Ortiz Corbella, Quoc-Hung Lê, Franck E. Nicolini, Anne Thiébaut, Xavier Thomas, Youcef Chelgoum, Sophie Ducastelle, Isabelle Mollet, Valérie Dubois, Mauricette Michallet
Journal: Blood (2006)
Enhanced T Cell Function in Patients with Hematological Malignanicies Undergoing Mobilization for Autologous Stem Cell Transplantation.
Authors: Adriana I. Colovai, Joseph Schwartz, Ronit Slotky, Zhouru Liu, Jianshe Fan, Nida Kabbaj, David G. Savage, Ajai Chari, Steven L. Spitalnik, Nicole Suciu-Foca
Journal: Blood (2007)